Pharmacovigilance and Risk Management Strategies 2013

Renaissance Washington DC Downtown Hotel
Washington, DC

Tutorials: January 13
Meeting: January 14-16

PROGRAM CHAIRPERSON

Mariette Boerstoel-Streefland, MD, MBA, MS(epi)
Chief Safety Officer, Vice President Global Drug Safety
Forest Research Institute, a Subsidiary of Forest Laboratories Inc.

PROGRAM CO-CHAIRPERSON

Jean-Pierre Clement, MD
Pharmacovigilance Professional

PROGRAM COMMITTEE

William W. Gregory
Senior Director, Safety and Risk Management
Pfizer Inc.

Steve Jolley
Principal, SJ Pharma Consulting
Chairperson for Clinical Safety and Pharmacovigilance SIAC

Michael Richardson
International Head GPV&E and EU QPPV
Bristol-Myers Squibb

Valerie E. Simmons, MD, FFPM
EU QPPV, Global Patient Safety
Eli Lilly & Company Ltd., United Kingdom

Melissa M Truffa, RPh
Associate Director
Office of Surveillance and Epidemiology/Division of Pharmacovigilance II
CDER, FDA

Shinya Yamauchi
Head of Pharmacovigilance Department
Otsuka Pharmaceutical Co., Ltd., Japan

LEARNING OBJECTIVES

At the conclusion of this meeting, participants should be able to:

- Describe the current regulatory framework for pharmacovigilance in the US, Europe, Japan, China, Brazil and Canada
- Describe operational challenges of implementing global benefit-risk analyses and risk management plans
- Discuss how social media is impacting pharmacovigilance
- Examine the role of epidemiology in safety analysis

DIA WORLDWIDE HEADQUARTERS
800 Enterprise Road, Suite 200
Horsham, PA 19044, USA

WOLRDWIDE OFFICES
Basel, Switzerland I Beijing, China I Tokyo, Japan
Mumbai, India I Washington, DC, USA

Current Complexities and Controversies in Pharmacovigilance, Signal, and Risk Management

This global three-day program will provide new insights into the current issues and associated challenges impacting drug safety, focusing primarily on drug products and biologics, throughout all phases of development and marketed use. Top pharmaceutical, biotech and regulatory representatives who are experts in their field will discuss new and updated legislation in various ICH regions, current regulatory framework for pharmacovigilance in global regions, operational challenges of implementing global benefit-risk analyses and risk management plans, the impact of social media, and the role of epidemiology in safety analysis.

This program was developed by the DIA Clinical Safety and Pharmacovigilance Special Interest Area Community

SESSION TOPICS

- Global regulatory updates
- New EU regulations
- Periodic benefit-risk Evaluation Reports
- Benefit-risk Analysis
- Use of existing automated databases
- Epidemiology
- Social media

WHO SHOULD ATTEND

Professionals with intermediate to advanced knowledge of, and experience in, clinical safety and who are involved in:

- Pharmacovigilance
- Drug Safety
- Risk management
- Medical product safety assessment
- Regulatory affairs
- Clinical research
- Data analysis
- Pharmacoepidemiology
- Medical information
- Health Outcomes

It is also designed for professionals who work for:

- Industry: pharmaceuticals and biologics
- Clinical Research Organizations
- Academic Research Centers
- Regulatory Agencies

DIA®
www.diahome.org

CONTINUING EDUCATION CREDITS

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Drug Information Association. PIM is accredited by the ACCME to provide continuing medical education for physicians.

PIM designates this live activity for a maximum of 16.25 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designated for up to 9.25 contact hours or .925 continuing education units (CEU's).

Type of Activity: Knowledge

DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA's My Transcript **within 45-days post activity.** Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net.

Corexcel is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Corexcel designates this activity for a maximum of 22.75 contact hours.

Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET),
1760 Old Meadow Road, Suite 500, McLean, VA 22102.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer up to 2.2 CEUs for the program. Participants must attend the entire program <and tutorial(s), if applicable> in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

DIA's Certificate Program

This program is part of DIA's Certificate Program and is awarded the following:

- Clinical Safety and Pharmacovigilance Certificate Program: 4 Elective Units

For more information go to www.diahome.org/certificateprograms

CONTINUING EDUCATION CREDIT ALLOCATION

Tutorial #1, Pharmacovigilance and Risk Management Planning: Pharmacy: 3.25 contact hours or .325 CEUs, 0286-0000-13-001-L04-P; Nursing: 3.25 contact hours; IACET: .3 CEUs
Tutorial #2, Development Safety Update Reports (DSURs): Principles and Practicalities: Nursing: 3.25 contact hours; IACET: .3 CEUs
Tutorial #3, ICH E2C (R2); The Quantum Leap from PSURs to Benefit Risk Evaluation (PBRERs): Nursing: 3.25 contact hours; IACET: .3 CEUs
Tutorial #4, Pharmacovigilance System Master File: Nursing: 3.25 contact hours; IACET: .3 CEUs

Program:
CME: 16.25 AMA PRA Category 1 Credit(s)TM
Nursing: 16.25 contact hours
IACET: 1.6 CEUs
Pharmacy:
Session 2 – FDA Updates: 1.5 contact hours or .15 CEUs, 0286-0000-13-002-L04-P
Session 4 – Debate: Controversies in Pharmacovigilance – Blind or Unblind: 1.5 contact hours or .15 CEUs, 0286-0000-13-003-L04-P
Session 10 – Epidemiology: 1.5 contact hour or .15 CEU, 0286-0000-13-004-L04-P
Session 11 – Social Media Panel Discussion: 1.5 contact hours or .15 CEUs, 0286-0000-13-005-L04-P

If you would like to receive a statement of credit, you must attend the program <and tutorial, if applicable>, scan your name badge at the DIA registration desk each day of the program, and complete the on-line credit request process through My Transcript. To access My Transcript, please go to www.diahome.org, select "Login to My DIA" and you will be prompted for your user ID and password. Select "My Transcript" (left side bar) and "Credit Request" to process your credit request. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Wednesday, January 30, 2013.

Disclosure Policy

The Postgraduate Institute for Medicine (PIM) and DIA require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and DIA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association.

Speakers, agenda, and CE information are subject to change without notice.

Recording of any DIA educational material in any type of media, is prohibited without prior written consent from DIA.

To view DIA's Grievance Policy, please visit the CE page on DIA's website at www.diahome.org.

TUTORIAL DAY | **SUNDAY, JANUARY 13**

AM tutorials – run from 8:30 AM-12:00 PM (with a 15 min break)

PM tutorials – run from 1:30-5:00 PM (with a 15 min break)

Lunch is not provided for tutorial attendees

8:30 AM – 12:00 PM CONCURRENT TUTORIALS – #1 AND #2

Tutorial #1 – Pharmacovigilance and Risk Management Planning

Tutorial Instructors:

William W. Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc.

This tutorial will focus on the practical aspects of managing biopharmaceutical product risks in the context of a product's benefits.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

- Discuss similarities and differences in risk management planning in the three ICH regions
- Describe the differences between important identified risks and important potential risks
- Outline the basic structure and contents of an EU Risk Management Plan (in the context of a Risk Management System) and a Risk Evaluation and Mitigation Strategy (REMS)
- Discuss primary tools for managing product risks, how the effectiveness of a selected tool is assessed, and triggers for modification or removal of a given intervention

Tutorial #2 - Development Safety Update Reports (DSURs): Principles and Practicalities

Tutorial Instructor

Michael Richardson
International Head GPV&E and EU QPPV
Bristol-Myers Squibb, UK

Tutorial Description

The new ICH E2F guideline on the Development Safety Update Report (DSUR) was signed off in August 2010 and came into force in Europe in September 2011. This new report will replace the current European clinical trial Annual Safety Report and, in the other ICH regions is intended to be a common standard for periodic reporting on drugs under development (including marketed drugs that are under further study).

Learning Objectives:

At the conclusion of this activity, participants should be able to:

- Discuss the main principles defined in the ICH E2F guideline
- Describe the structure and content of the DSUR
- Discuss how a DSUR can be prepared
- Review the implementation process of the DSUR

1:30 – 5:00 PM CONCURRENT TUTORIALS – #3 AND #4

Tutorial #3 – ICH E2C (R2); The Quantum Leap from PSURs to Benefit Risk Evaluation (PBRERs)

Tutorial Instructors

Valerie E. Simmons, MD, FFPM
EU QPPV, Global Patient Safety
Eli Lilly and Company Limited, UK

Amanda McDaniel
Consultant, Risk Management Coordination
Eli Lilly and Company

Ayman Ayoub, MD, MS, MPhil
Disease Area Head,
Safety Surveillance and Risk Management
Pfizer

Tutorial Description

The new ICH E2C (E2C) guideline on Periodic Benefit Risk Evaluation Reports reached Step 2 in February 2012 and completed Step 4 in November 2012. Already implemented in the EU under the new Pharmacovigilance legislation, this new report represents a significant change from the previous PSUR format and a quantum leap forward towards a document incorporating many new concepts including an integrated evaluation of both benefits and risks of a medicinal product .In the other ICH regions, the PBRER is intended to replace existing requirements for post marketing periodic reporting.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

- Discuss the main principles defined in the ICH E2C (R2) guideline
- Describe the structure and content of the new PBRER
- Explain the regulatory authority expectations of the PBRER
- Recognize how to implement the PBRER to encompass multiple functions
- Discuss the practical aspects in the preparation of the PBRER

1:30 – 5:00 PM CONCURRENT TUTORIALS – #3 AND #4 (CONTINUED)

Tutorial #4 - Pharmacovigilance System Master File

Tutorial Instructor

Noha Kassem, PhD
Senior Director of Quality in Global Patient Safety
Eli Lilly and Company, UK

As part of the new EU Pharmacovigilance Legislation (Regulation EU 1235/2010 and Directive 2010/84/EU) marketing-authorisation holders are required to maintain a Pharmacovigilance System Master File (PSMF). The PSMF must be in place at the time of initial marketing authorization application, license renewal and available for inspections. The PSMF replaced the Detailed Description of the Pharmacovigilance System (DDPS). This tutorial will cover the requirements in the PSMF, the creation and maintenance as well as sharing a real experience focusing on some of challenges and how they can be addressed.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

- Discuss how to prepare a PSMF to meet the requirements
- Describe how to maintain a PSMF so that it can be available within 7days from request
- Examine challenges and possible scenarios of how to address preparation and maintenance

CONFERENCE DAY 1 | **MONDAY, JANUARY 14**

7:45 – 8:45 AM CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:45 – 9:00 AM CONFERENCE WELCOME

Paul Pomerantz
Worldwide Executive Director, DIA

9:00 – 9:15 AM PROGRAM COMMITTEE OPENING REMARKS

Program Chairperson

Mariette Boerstoel-Streefland, MD, MBA, MS(epi)
Chief Safety Officer, VP Global Drug Safety,
Forest Research Institute, Forest Laboratories Inc.

Program Co-Chairperson

Jean-Pierre Clement, MD
Vice President and Head of International Pharmacovigilance
Global Medical Safety
Division of Johnson & Johnson Pharmaceutical R&D

9:15 – 10:00 AM SESSION 1

Keynote Presentation

Session Chairperson

Mariette Boerstoel-Streefland, MD, MBA, MS(epi)
Chief Safety Officer, Vice President Global Drug Safety
Forest Research Institute, a Subsidiary of Forest Laboratories Inc.

From Drug Safety to Risk Management: Where Have We Been and Where Are We Going?

Keynote Speaker

David Goldsmith, MD
President, Senior Consultant
Goldsmith Pharmacovigilance and Systems

10:00 – 10:30 AM REFRESHMENT BREAK

10:30 AM – 11:30 AM SESSION 2

FDA Updates

Session Chairperson

Melissa M Truffa, RPh
Associate Director
Office of Surveillance and Epidemiology/Division of Pharmacovigilance II
CDER, FDA

Regulatory Updates from the FDA

Gerald J. Dal Pan, MD
Director, Office of Surveillance and Epidemiology, CDER
FDA

DSUR Update - FDA Perspective

Ellis Unger, MD
Deputy Director, Office of Drug Evaluation-I, OND, CDER
FDA

11:30 AM – 12:00 PM Q & A (ALL SESSION SPEAKERS)

12:00 – 1:30 PM LUNCH

1:30 – 2:30 PM SESSION 3

What's New in Japan – Practicalities of Implementation of Risk Management Plans (RMPs)

SESSION CHAIRPERSON

William W. Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer, Inc.

What's New in Japan - Industry View on Practicalities of Implementation of RMPs

Stewart Geary, MD
Vice President, Deputy Director
Eisai Co., Ltd., Japan

Pharmacovigilance in Japan and Risk Management Plans (RMP); Regulator Perspective

Kazuhiko Mori, MS
Chief Safety Officer
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

2:30 – 3:00 PM Q & A (ALL SESSION SPEAKERS)

3:00 – 3:30 PM REFRESHMENT BREAK

3:30 – 5:00 PM SESSION 4

Session 4 – Debate: Controversies in Pharmacovigilance – Blind or Unblind

SESSION CHAIRPERSON

Michael Richardson
International Head GPV&E and EU QPPV
Bristol-Myers Squibb

Unblind Point of View/Regulatory Perspective

Robert J. Temple, MD
Deputy Center Director for Clinical Science, CDER
FDA

Blind Point of View/Industry Perspective

David Goldsmith, MD
President, Senior Consultant
Goldsmith Pharmacovigilance and Systems

Statistician Perspective

Christy Chuang-Stein, PhD
Vice President, Statistics
Pfizer, Inc.

5:00 PM END OF DAY 1

5:00 – 6:00 PM NETWORKING RECEPTION1

CONFERENCE DAY 2 | **TUESDAY, JANUARY 15**

7:30 – 8:30 AM CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:30 – 10:00 AM SESSION 5

Session 5 – New EU Regulations – Part A – Regulatory Overview

SESSION CHAIRPERSON

Valerie E. Simmons, MD, FFPM
EU QPPV, Global Patient Safety
Eli Lilly & Company Ltd., United Kingdom

EU Regulations – Regulatory Overview (presentation will be given via webinar)

Stella Blackburn, MBBS
EMA Risk Management Development and Scientific Lead
European Medicines Agency, European Union

EU Regulations – Non-regulatory Overview

Richard F. Kingham, Esq
Partner
Covington & Burling, LLP

10:00 – 10:30 AM REFRESHMENT BREAK

10:30 – 11:30 AM SESSION 6

New EU Regulations – Part B – Industry View/Impact

SESSION CHAIRPERSON

Valerie E. Simmons, MD, FFPM
EU QPPV, Global Patient Safety
Eli Lilly & Company Ltd., United Kingdom

New EU Regulations - An Industry Diagnostic

Jennifer Markey
Director, Consulting
Deloitte MCS Limited, UK

New EU Regulations – Industry Impact

Vicki R. Edwards
QPPV and Head of Affiliate Vigilance Excellence
Global Pharmacovigilance
Global Medical Services
Abbott Laboratories, UK

11:30 AM – 12:00 PM Q & A (ALL SESSION SPEAKERS AND Q&A PARTICIPANT)

Q & A PARTICIPANT

Marc Berthiaume, MD
Director, Marketed Pharmacologicals and Medical Devices Bureau, MHPD
Health Canada, Canada

12:00 – 1:30 PM LUNCH

1:30 – 3:00 PM SESSION 7

Benefit-risk Analysis – Operational Challenges

SESSION CHAIRPERSON

William W. Gregory
Senior Director, Safety and Risk Management
Pfizer Inc.

CIOMS IX Update

William W. Gregory
Senior Director, Safety and Risk Management
Pfizer Inc.

Practical Approaches and Challenges in Assessing Benefit Risk for Innovator Products

Nayan Acharya, MD
Senior Director, Office of Risk Management & Pharmacoepidemiology
Eli Lilly and Company

Benefit-Risk Analysis for Mature Products: Value and Challenges

Ayman Ayoub, MD, MS, MPhil
Disease Area Head, Safety Surveillance and Risk Management
Pfizer

3:00 – 3:30 PM REFRESHMENT BREAK

3:30 – 4:30 PM SESSION 8

Panel Debate: Will We Ever Move Towards More Quantitative Benefit-risk Analysis?

SESSION CHAIRPERSON

Bennett Levitan, MD, PhD
Director, Epidemiology
Janssen Research & Development, LLC

PANELISTS

Kazuhiko Mori, MS
Chief Safety Officer
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Rebecca Noel, DrPH, MSPH
Research Scientist, Global Patient Safety
Eli Lilly and Company

Paul Coplan, MS, ScD, MBA
Executive Director, Risk Management and Epidemiology
Purdue Pharma LP

Patrick Frey
Director, Office of Planning and Analysis
CDER, FDA

4:30 – 5:00 PM Q & A (ALL SESSION SPEAKERS)

5:00 PM END OF DAY 2

CONFERENCE DAY 3 | **WEDNESDAY, JANUARY 16**

7:30 – 8:30 AM CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:30 – 10:00 AM SESSION 9

Other International Regulatory Updates

SESSION CHAIRPERSON

Jean-Pierre Clement, MD
Pharmacovigilance Professional

Updates on China Pharmacovigilance Regulatory Requirements

Speaker Invited

Brazil Pharmacovigilance Regulatory Updates

Adalton G. Ribeiro
Pharmacovigilance Diretor
Health Surveillance Center CVS-SES-SP, Brazil

Canada Pharmacovigilance Regulatory Updates

Marc Berthiaume, MD
Director, Marketed Pharmacologicals and Medical Devices Bureau, MHPD
Health Canada, Canada

10:00 – 10:30 AM REFRESHMENT BREAK

10:30 – 11:30 AM SESSION 10

Epidemiology

SESSION CHAIRPERSON

Mariette Boerstoel-Streefland, MD, MBA, MS
Chief Safety Officer, Vice President-Global Drug Safety
Forest Research Institute

Opportunities and Challenges Associated with the Use of Existing Automated Databases in the Assessment of Drug Safety

Jesse A. Berlin, DrSc
Vice President, Epidemiology
Janssen Research & Development LLC

Role of Observational Data in Regulatory Decision Making: The Drug Safety Paradigm

Tarek A. Hammad, MD, PhD, MSc, MS
Deputy Division Director, Division of Epidemiology
Office of Pharmacovigilance and Epidemiology (OPE)
Office of Surveillance and Epidemiology
CDER, FDA

11:30 AM – 12:00 PM Q & A (ALL SESSION SPEAKERS)

12:00 – 1:30 PM LUNCH

1:30 – 3:00 PM SESSION 11

Social Media Panel Discussion

SESSION CHAIRPERSON

Elizabeth E. Garrard, PharmD
Consultant
Garrard Safety Solutions

PANELISTS

Linda J. Scarazzini, MD
Director of Division of Pharmacovigilance I, CDER
FDA

Michael A. Ibara, PharmD
Head of Business Development Coordination and Innovation
Worldwide Safety and Regulatory Operations
Pfizer, Inc.

Brian M. Overstreet
President
AdverseEvents

John S. Brownstein, PhD, MPhil
Manager and Associate Professor
Boston Children's Hospital and Harvard Medical School

3:00 PM END OF DAY 3 – CONFERENCE ADJOURNS

REGISTRATION FORM
Register online or fax this page to +1.215.442.6199

Pharmacovigilance and Risk Management Strategies 2013
Event #13002 • Tutorials: January 13, 2013 • January 14-16, 2013
Renaissance Washington DC Downtown Hotel, Washington, DC

Registration Fees If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

Member Early-bird Opportunity Available on nondiscount member fee only	On or before DEC. 19, 2012	After DEC. 19, 2012
Member Fee	US $1465 ❑	US $1665 ❑

Join DIA now to qualify for the early-bird member fee!
www.diahome.org/Membership

MEMBERSHIP
US $175 ❑

To qualify for the early-bird discount, registration form and accompanying payment must be received by the date above. Does not apply to government/academia/nonprofit members.

Nonmember Fee US $1840 ❑

A one-year membership to DIA is available to those paying a nonmember registration fee. *If paying a nonmember fee, please indicate if you do, or do not, want membership.

I want to be a DIA member ❑ I do NOT want to be a DIA member ❑

Discount Fees	MEMBER	NONMEMBER
Government (Full-time)	US $665 ❑	US $840 ❑
Charitable Nonprofit/Academia (Full-time)	US $835 ❑	US $1010 ❑

**If paying a nonmember fee, please check one box above, indicating whether you want membership.*

TUTORIALS: January 13, 2013

Half-day Morning – 8:30 AM-12:00 PM

Tutorial #1 – Pharmacovigilance and Risk Management Planning	US $405 ❑
Tutorial #2 - Development Safety Update Reports (DSURs): Principles and Practicalities	US $405 ❑

Half-day Afternoon: 1:30-5:00 PM

Tutorial #3 – ICH E2C (R2); The Quantum Leap from PSURs to Benefit Risk Evaluation (PBRERs)	US $405 ❑
Tutorial #4 - Pharmacovigilance System Master File	US $405 ❑

GROUP DISCOUNTS* Register 3 individuals from the same company and receive complimentary registration for a 4th! **All 4 individuals must register and prepay at the same time – no exceptions.** DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. **Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.** To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

❑ **Please indicate that this form is part of a group registration by checking this box and list below the names of the other three registrants from your company.**

1. _____

2. _____

3. _____

Payment options: Register online at www.diahome.org or check payment method.

❑ **CREDIT CARD** number may be faxed to: +1.215.442.6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

☐ **Visa** ☐ **MC** ☐ **AMEX** Exp Date_____

Card # _____

Name (printed) _____

Signature _____

❑ **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

❑ **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

TRAVEL AND HOTEL The most convenient airport is Ronald Reagan Washington National Airport - DCA and attendees should make airline reservations as early as possible to ensure availability. Renaissance Washington DC Downtown Hotel is holding a block of rooms at the reduced rate below until December 28, 2012 for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $249 **Double $249**

Attendees must make their own hotel reservations. Contact the Renaissance Washington DC Downtown Hotel by telephone at +1.202.898.9000 or 1.800.468.3571 and mention the DIA event. The hotel is located at 999 Ninth Street NW, Washinton, DC 20001, USA.

CANCELLATION POLICY: On or before JANUARY 7, 2013
Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academia or Nonprofit (Member or Nonmember) = $100
Preconference Workshop (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

TABLETOP EXHIBIT INFORMATION

Attendees may visit the tabletop exhibits during the event and receptions.
Contact **Jeff Korn, Exhibits Associate,** Phone **+1.215.442.6184**
Fax **+1.215.442.6199,** email **Jeff.Korn@diahome.org**

EVENT INFORMATION

For registration questions, please contact **Marilyn Ginsberg** by phone at **+1.215.442.6135** or by email at **Marilyn.Ginsberg@diahome.org**.

For event details, please contact **Ellen Diegel** by phone at **+1.215.293.5810** or by email at **Ellen.Diegel@diahome.org.**

Please check the applicable category:

❑ Academia ❑ Government ❑ Industry ❑ CSO ❑ Student
(Call for registration information)

Last Name _____

First Name _____ M.I.

Degrees _____ ❑ Dr. ❑ Mr. ❑ Ms.

Job Title _____

Company _____

Address (As required for postal delivery to your location) _____ Mail Stop

City _____ State Zip/Postal Country

email **Required for confirmation**

Phone Number _____ Fax Number **Required for confirmation**